These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 33072564)
1. Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis. Chen J; Ni Y; Sun G; Liao B; Zhang X; Zhao J; Zhu S; Wang Z; Shen P; Zeng H Front Oncol; 2020; 10():519388. PubMed ID: 33072564 [No Abstract] [Full Text] [Related]
3. Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. Jian T; Zhan Y; Hu K; He L; Chen S; Hu R; Lu J Front Pharmacol; 2022; 13():955925. PubMed ID: 36278154 [No Abstract] [Full Text] [Related]
4. Combination therapy for high-volume Jian T; Zhan Y; Yu Y; Yu K; Hu R; Wang J; Lu J Front Pharmacol; 2023; 14():1148021. PubMed ID: 37153773 [No Abstract] [Full Text] [Related]
5. Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer. Wang SS; Bian XJ; Wu JL; Wang BH; Zhang S; Ye DW Asian J Androl; 2024 Jul; 26(4):402-408. PubMed ID: 38624195 [TBL] [Abstract][Full Text] [Related]
6. Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. Sathianathen NJ; Koschel S; Thangasamy IA; Teh J; Alghazo O; Butcher G; Howard H; Kapoor J; Lawrentschuk N; Siva S; Azad A; Tran B; Bolton D; Murphy DG Eur Urol; 2020 Mar; 77(3):365-372. PubMed ID: 31679970 [TBL] [Abstract][Full Text] [Related]
7. Comparison of doublet and triplet therapies for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. Wang L; Li C; Zhao Z; Li X; Tang C; Guan Z; Sun F; Gu J; Li N Front Oncol; 2023; 13():1104242. PubMed ID: 36959793 [TBL] [Abstract][Full Text] [Related]
8. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. Wenzel M; Würnschimmel C; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Roos FC; Mandel P; Chun FKH; Karakiewicz PI Eur Urol Focus; 2022 Mar; 8(2):399-408. PubMed ID: 33853754 [TBL] [Abstract][Full Text] [Related]
9. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809 [TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513 [TBL] [Abstract][Full Text] [Related]
12. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. Mori K; Mostafaei H; Sari Motlagh R; Pradere B; Quhal F; Laukhtina E; Schuettfort VM; Kramer G; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF BJU Int; 2022 Apr; 129(4):423-433. PubMed ID: 34171173 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. Wang L; Paller CJ; Hong H; De Felice A; Alexander GC; Brawley O JAMA Oncol; 2021 Mar; 7(3):412-420. PubMed ID: 33443584 [TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy of Combined Radiotherapy, Systemic Therapy, and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-Analysis and Systematic Review. Wang Y; Gui H; Wang J; Tian J; Wang H; Liang C; Hao Z; Rodriguez R; Wang Z Front Oncol; 2020; 10():567616. PubMed ID: 33194648 [No Abstract] [Full Text] [Related]
15. Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis. Tan PS; Aguiar P; Haaland B; Lopes G Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):516-523. PubMed ID: 29875432 [TBL] [Abstract][Full Text] [Related]
16. The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis. Mutlu H; Bozcuk H J Cancer Res Ther; 2023; 19(2):394-402. PubMed ID: 37313915 [TBL] [Abstract][Full Text] [Related]
17. Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis. Zhou Z; Liu S; Mei J; Liu T; Liu F; Zhang G Acta Oncol; 2023 Sep; 62(9):1083-1090. PubMed ID: 37548225 [TBL] [Abstract][Full Text] [Related]
18. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy. Kassem L; Shohdy KS; Abdel-Rahman O Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505 [TBL] [Abstract][Full Text] [Related]
19. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume. Hoeh B; Garcia CC; Wenzel M; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH; Mandel P Eur Urol Focus; 2023 Sep; 9(5):838-842. PubMed ID: 37055323 [TBL] [Abstract][Full Text] [Related]
20. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]